FRANKFURT, Oct 29 (Reuters) - Bayer (BAYG.DE: Quote, Profile, Research) will take a 152 million-euro ($218 million) impairment charge after its higher dose multiple-sclerosis drug Betaferon failed to show it could work better than the standard dose Betaferon and rival Teva’s (TEVA.O: Quote, Profile, Research) Copaxone, the German company said on Monday.
